Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paracetamol + caffeine + propyphenazone
- Development stage
- Unknown
- Lead developer
- Pannonpharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Miralgin is a combination analgesic and antipyretic medication developed and marketed by the Hungarian pharmaceutical company PannonPharma. It is formulated as an oral tablet containing three active ingredients: paracetamol (acetaminophen), propyphenazone (a pyrazolone derivative), and caffeine. Paracetamol and propyphenazone work synergistically to provide pain relief and reduce fever by inhibiting prostaglandin synthesis in the central nervous system and peripheral tissues. Caffeine acts as an analgesic adjuvant, enhancing the efficacy and speed of onset of the pain-relieving components while providing a mild stimulant effect. Miralgin is primarily indicated for the short-term treatment of acute pain conditions, such as headaches, toothaches, and menstrual pain (dysmenorrhea), as well as for the management of fever.
- Brand names
- Miralgin
- Other names
- Miralgin
02
Targets
ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on paracetamol + caffeine + propyphenazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paracetamol + caffeine + propyphenazone.